HLS Therapeutics (TSE:HLS) Shares Up 0.5% – Still a Buy?

HLS Therapeutics Inc. (TSE:HLS) shares traded up 0.5% during mid-day trading on Thursday. The stock traded as high as C$4.15 and last traded at C$4.15. 7,100 shares changed hands during trading, a decline of 80% from the average session volume of 35,203 shares. The stock had previously closed at C$4.13.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Canaccord Genuity Group raised HLS Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 13th. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from C$7.00 to C$8.00 in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Strong Buy” and an average price target of C$8.00.

HLS Therapeutics Stock Performance

The firm has a market capitalization of C$133.95 million, a price-to-earnings ratio of -16.04 and a beta of -0.50. The company has a debt-to-equity ratio of 75.86, a current ratio of 1.05 and a quick ratio of 1.01. The firm has a 50 day moving average price of C$3.95 and a 200-day moving average price of C$4.23.

HLS Therapeutics (TSE:HLS) last released its earnings results on Wednesday, August 12th. The company reported C($0.03) EPS for the quarter. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%. The company had revenue of C$14.67 million for the quarter. During the same period last year, the firm earned ($0.09) earnings per share. As a group, sell-side analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.